RecruitingPhase 1NCT07072234
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Sponsor
M.D. Anderson Cancer Center
Enrollment
30 participants
Start Date
Sep 25, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This Phase I trial tests a new type of cell therapy called allogeneic CAR NK cells (donor immune cells engineered to attack a protein called CD70) in patients with metastatic or unresectable clear cell kidney cancer that no longer responds to standard treatments. This is a first-in-human safety study.
**You may be eligible if...**
- You have advanced clear cell renal cell carcinoma (kidney cancer) confirmed by biopsy
- Your cancer cannot be surgically removed or has spread
- Standard treatments have stopped working
- Your tumor expresses CD70 (a protein confirmed by a lab test on your tumor tissue)
**You may NOT be eligible if...**
- Your kidney cancer does not express CD70
- You still have effective standard treatment options available
- You have serious immune system problems or active infections
- You are pregnant or breastfeeding
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLymphodepleting chemotherapy
Given by IV
DRUGDexamethasone
Given PO
DRUGFludarabine
Given by IV
DRUGCyclophosphamate
Given by IV
DRUGTGFBR-2 KO CD70 CAR NK
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07072234
Related Trials
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
NCT066604201 location
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT0546000047 locations
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
NCT046235021 location
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT0602386218 locations